Astrazeneca Plc Adr Stock Gross Profit

AZN Stock

USD 67.62 0.42 0.63%

AstraZeneca PLC ADR fundamentals help investors to digest information that contributes to AstraZeneca PLC's financial success or failures. It also enables traders to predict the movement of AstraZeneca Stock. The fundamental analysis module provides a way to measure AstraZeneca PLC's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to AstraZeneca PLC stock.

	Last Reported	Projected for Next Year
Gross Profit	37.8 B	19.9 B
Gross Profit Margin	0.82	0.87

As of the 1st of December 2024, Gross Profit Margin is likely to grow to 0.87, while Gross Profit is likely to drop about 19.9 B.

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

AstraZeneca PLC ADR Company Gross Profit Analysis

AstraZeneca PLC's Gross Profit is the most basic measure of business operational efficiency. It is simply the difference between sales revenue and the cost associated with making a product or providing a service. It is calculated before deducting administrative expenses, taxes, and interest payments.

Gross Profit

Revenue

-

Cost of Revenue

More About Gross Profit | All Equity Analysis

Current AstraZeneca PLC Gross Profit

35.73 B

Most of AstraZeneca PLC's fundamental indicators, such as Gross Profit, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, AstraZeneca PLC ADR is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

AstraZeneca Gross Profit Driver Correlations

Understanding the fundamental principles of building solid financial models for AstraZeneca PLC is extremely important. It helps to project a fair market value of AstraZeneca Stock properly, considering its historical fundamentals such as Gross Profit. Since AstraZeneca PLC's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of AstraZeneca PLC's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of AstraZeneca PLC's interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Short Term Investments	Total Liab	Total Current Assets	Short Term Debt	Capital Stock	Common Stock	Intangible Assets	Long Term Debt	Good Will	Property Plant Equipment	Current Deferred Revenue	Net Receivables	Net Tangible Assets	Long Term Investments	Short Long Term Debt	Deferred Long Term Liab	Long Term Debt Total	Capital Surpluse	Net Invested Capital	Net Working Capital
Total Assets		0.9	0.85	-0.24	-0.25	-0.36	0.96	0.69	0.83	0.74	0.74	0.96	0.79	1.0	0.83	0.5	0.75	-0.66	0.69	-0.36	0.6	0.68	0.63	0.8	0.09
Total Stockholder Equity	0.9		0.65	-0.03	-0.37	-0.22	0.74	0.76	0.81	0.69	0.69	0.82	0.57	0.91	0.65	0.47	0.67	-0.3	0.41	0.01	0.26	0.48	0.51	0.84	-0.04
Net Debt	0.85	0.65		-0.67	-0.4	-0.53	0.89	0.34	0.78	0.65	0.65	0.9	0.81	0.86	0.87	0.61	0.8	-0.83	0.84	-0.46	0.82	0.83	0.7	0.81	0.15
Retained Earnings	-0.24	-0.03	-0.67		0.51	0.55	-0.36	0.15	-0.34	-0.38	-0.38	-0.37	-0.51	-0.26	-0.57	-0.61	-0.66	0.6	-0.71	0.37	-0.68	-0.57	-0.64	-0.5	-0.27
Accounts Payable	-0.25	-0.37	-0.4	0.51		0.36	-0.15	-0.19	-0.41	-0.37	-0.37	-0.23	-0.23	-0.25	-0.43	-0.72	-0.63	0.0	-0.29	-0.28	-0.16	-0.29	-0.53	-0.66	-0.12
Short Term Investments	-0.36	-0.22	-0.53	0.55	0.36		-0.42	0.1	-0.33	-0.22	-0.22	-0.47	-0.4	-0.36	-0.39	-0.44	-0.47	0.44	-0.49	0.36	-0.41	-0.43	-0.44	-0.43	-0.09
Total Liab	0.96	0.74	0.89	-0.36	-0.15	-0.42		0.58	0.76	0.69	0.69	0.96	0.86	0.95	0.86	0.48	0.72	-0.82	0.82	-0.57	0.76	0.74	0.66	0.7	0.17
Total Current Assets	0.69	0.76	0.34	0.15	-0.19	0.1	0.58		0.45	0.81	0.81	0.55	0.63	0.67	0.63	0.3	0.56	-0.12	0.39	-0.01	0.24	0.33	0.53	0.59	0.25
Short Term Debt	0.83	0.81	0.78	-0.34	-0.41	-0.33	0.76	0.45		0.58	0.58	0.8	0.51	0.86	0.7	0.56	0.72	-0.51	0.6	-0.1	0.49	0.7	0.6	0.78	-0.33
Capital Stock	0.74	0.69	0.65	-0.38	-0.37	-0.22	0.69	0.81	0.58		1.0	0.72	0.87	0.74	0.86	0.48	0.82	-0.47	0.72	-0.25	0.59	0.54	0.77	0.81	0.27
Common Stock	0.74	0.69	0.65	-0.38	-0.37	-0.22	0.69	0.81	0.58	1.0		0.72	0.87	0.74	0.86	0.48	0.82	-0.47	0.72	-0.25	0.59	0.54	0.77	0.81	0.27
Intangible Assets	0.96	0.82	0.9	-0.37	-0.23	-0.47	0.96	0.55	0.8	0.72	0.72		0.82	0.97	0.81	0.46	0.72	-0.78	0.73	-0.47	0.68	0.66	0.59	0.8	0.11
Long Term Debt	0.79	0.57	0.81	-0.51	-0.23	-0.4	0.86	0.63	0.51	0.87	0.87	0.82		0.78	0.9	0.45	0.77	-0.77	0.86	-0.56	0.83	0.67	0.74	0.71	0.45
Good Will	1.0	0.91	0.86	-0.26	-0.25	-0.36	0.95	0.67	0.86	0.74	0.74	0.97	0.78		0.82	0.5	0.75	-0.66	0.69	-0.35	0.59	0.68	0.63	0.82	0.04
Property Plant Equipment	0.83	0.65	0.87	-0.57	-0.43	-0.39	0.86	0.63	0.7	0.86	0.86	0.81	0.9	0.82		0.69	0.9	-0.69	0.93	-0.4	0.83	0.83	0.91	0.8	0.24
Current Deferred Revenue	0.5	0.47	0.61	-0.61	-0.72	-0.44	0.48	0.3	0.56	0.48	0.48	0.46	0.45	0.5	0.69		0.87	-0.28	0.65	-0.02	0.43	0.52	0.86	0.66	0.12
Net Receivables	0.75	0.67	0.8	-0.66	-0.63	-0.47	0.72	0.56	0.72	0.82	0.82	0.72	0.77	0.75	0.9	0.87		-0.5	0.83	-0.2	0.63	0.69	0.95	0.87	0.2
Net Tangible Assets	-0.66	-0.3	-0.83	0.6	0.0	0.44	-0.82	-0.12	-0.51	-0.47	-0.47	-0.78	-0.77	-0.66	-0.69	-0.28	-0.5		-0.81	0.8	-0.89	-0.64	-0.47	-0.44	-0.2
Long Term Investments	0.69	0.41	0.84	-0.71	-0.29	-0.49	0.82	0.39	0.6	0.72	0.72	0.73	0.86	0.69	0.93	0.65	0.83	-0.81		-0.61	0.91	0.8	0.88	0.62	0.23
Short Long Term Debt	-0.36	0.01	-0.46	0.37	-0.28	0.36	-0.57	-0.01	-0.1	-0.25	-0.25	-0.47	-0.56	-0.35	-0.4	-0.02	-0.2	0.8	-0.61		-0.61	-0.32	-0.25	-0.07	-0.33
Deferred Long Term Liab	0.6	0.26	0.82	-0.68	-0.16	-0.41	0.76	0.24	0.49	0.59	0.59	0.68	0.83	0.59	0.83	0.43	0.63	-0.89	0.91	-0.61		0.79	0.68	0.48	0.21
Long Term Debt Total	0.68	0.48	0.83	-0.57	-0.29	-0.43	0.74	0.33	0.7	0.54	0.54	0.66	0.67	0.68	0.83	0.52	0.69	-0.64	0.8	-0.32	0.79		0.71	0.61	0.02
Capital Surpluse	0.63	0.51	0.7	-0.64	-0.53	-0.44	0.66	0.53	0.6	0.77	0.77	0.59	0.74	0.63	0.91	0.86	0.95	-0.47	0.88	-0.25	0.68	0.71		0.72	0.19
Net Invested Capital	0.8	0.84	0.81	-0.5	-0.66	-0.43	0.7	0.59	0.78	0.81	0.81	0.8	0.71	0.82	0.8	0.66	0.87	-0.44	0.62	-0.07	0.48	0.61	0.72		0.13
Net Working Capital	0.09	-0.04	0.15	-0.27	-0.12	-0.09	0.17	0.25	-0.33	0.27	0.27	0.11	0.45	0.04	0.24	0.12	0.2	-0.2	0.23	-0.33	0.21	0.02	0.19	0.13

Click cells to compare fundamentals

AstraZeneca Gross Profit Historical Pattern

Today, most investors in AstraZeneca PLC Stock are looking for potential investment opportunities by analyzing not only static indicators but also various AstraZeneca PLC's growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's gross profit growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of AstraZeneca PLC gross profit as a starting point in their analysis.

AstraZeneca PLC Gross Profit

Timeline

Gross Profit varies significantly from one sector to another and tells an investor how much money a business would have made if it didn't have to pay any overhead expenses such as salary, taxes, or rent.

Competition

Predict AstraZeneca PLC

Gross Profit Over Time

According to the company disclosure, AstraZeneca PLC ADR reported 35.73 B of gross profit. This is much higher than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The gross profit for all United States stocks is 30.52% lower than that of the firm.

AstraZeneca Gross Profit Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses AstraZeneca PLC's direct or indirect competition against its Gross Profit to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of AstraZeneca PLC could also be used in its relative valuation, which is a method of valuing AstraZeneca PLC by comparing valuation metrics of similar companies.

AstraZeneca PLC is currently under evaluation in gross profit category among its peers.

AstraZeneca PLC Current Valuation Drivers

We derive many important indicators used in calculating different scores of AstraZeneca PLC from analyzing AstraZeneca PLC's financial statements. These drivers represent accounts that assess AstraZeneca PLC's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of AstraZeneca PLC's important valuation drivers and their relationship over time.

	2019	2020	2021	2022	2023	2024 (projected)
Market Cap	131.1B	131.2B	166.5B	209.9B	210.9B	253.6B
Enterprise Value	144.0B	143.8B	191.0B	232.9B	233.7B	269.0B

AstraZeneca PLC ESG Sustainability

Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, AstraZeneca PLC's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to AstraZeneca PLC's managers, analysts, and investors.

Environmental

Governance

Social

AstraZeneca Fundamentals

	Return On Equity	0.17
	Return On Asset	0.085
	Profit Margin	0.13 %
	Operating Margin	0.20 %
	Current Valuation	235.48 B
	Shares Outstanding	3.1 B
	Shares Owned By Institutions	16.75 %
	Number Of Shares Shorted	8.07 M
	Price To Earning	103.39 X
	Price To Book	5.15 X
	Price To Sales	4.09 X
	Revenue	45.81 B
	Gross Profit	35.73 B
	EBITDA	13.42 B
	Net Income	6.9 B
	Cash And Equivalents	4.52 B
	Cash Per Share	1.46 X
	Total Debt	28.62 B
	Debt To Equity	0.89 %
	Current Ratio	0.81 X
	Book Value Per Share	26.27 X
	Cash Flow From Operations	10.35 B
	Short Ratio	1.23 X
	Earnings Per Share	2.08 X
	Price To Earnings To Growth	0.73 X
	Target Price	88.27
	Number Of Employees	89.9 K
	Beta	0.18
	Market Capitalization	209.66 B
	Total Asset	101.12 B
	Retained Earnings	4.52 B
	Working Capital	(5.49 B)
	Current Asset	16.01 B
	Current Liabilities	14.87 B
	Annual Yield	0.02 %
	Five Year Return	2.99 %
	Net Asset	101.12 B
	Last Dividend Paid	2.97

About AstraZeneca PLC Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze AstraZeneca PLC ADR's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of AstraZeneca PLC using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of AstraZeneca PLC ADR based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Pair Trading with AstraZeneca PLC

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if AstraZeneca PLC position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in AstraZeneca PLC will appreciate offsetting losses from the drop in the long position's value.

Moving together with AstraZeneca Stock

0.78	HLN	Haleon plc	Pair Corr
0.9	JNJ	Johnson Johnson Sell-off Trend	Pair Corr
0.81	PFE	Pfizer Inc Aggressive Push	Pair Corr
0.81	ANRO	Alto Neuroscience,	Pair Corr

Moving against AstraZeneca Stock

0.83	AXP	American Express Fiscal Year End 24th of January 2025	Pair Corr
0.78	FNMFO	Federal National Mortgage	Pair Corr
0.77	TRV	The Travelers Companies Fiscal Year End 17th of January 2025	Pair Corr
0.47	ITCL	Banco Ita Chile	Pair Corr
0.44	KB	KB Financial Group	Pair Corr

The ability to find closely correlated positions to AstraZeneca PLC could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace AstraZeneca PLC when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back AstraZeneca PLC - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling AstraZeneca PLC ADR to buy it.

The correlation of AstraZeneca PLC is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as AstraZeneca PLC moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if AstraZeneca PLC ADR moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for AstraZeneca PLC can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

When determining whether AstraZeneca PLC ADR offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of AstraZeneca PLC's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Astrazeneca Plc Adr Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Astrazeneca Plc Adr Stock:

How To Invest In AstraZeneca

Details

Is AstraZeneca Stock a good investment?

Details

What is AstraZeneca PLC's Net Worth?

Details

Largest Pharmaceuticals Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out AstraZeneca PLC Piotroski F Score and AstraZeneca PLC Altman Z Score analysis.

You can also try the Portfolio Dashboard module to portfolio dashboard that provides centralized access to all your investments.

Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of AstraZeneca PLC. If investors know AstraZeneca will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about AstraZeneca PLC listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

0.034

Dividend Share

2.97

Earnings Share

2.08

Revenue Per Share

2.7424

Quarterly Revenue Growth

0.18

The market value of AstraZeneca PLC ADR is measured differently than its book value, which is the value of AstraZeneca that is recorded on the company's balance sheet. Investors also form their own opinion of AstraZeneca PLC's value that differs from its market value or its book value, called intrinsic value, which is AstraZeneca PLC's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because AstraZeneca PLC's market value can be influenced by many factors that don't directly affect AstraZeneca PLC's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between AstraZeneca PLC's value and its price as these two are different measures arrived at by different means. Investors typically determine if AstraZeneca PLC is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, AstraZeneca PLC's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Astrazeneca Plc Adr Stock Gross Profit

AstraZeneca PLC ADR Company Gross Profit Analysis

Gross Profit

Revenue

-

Cost of Revenue

Current AstraZeneca PLC Gross Profit

AstraZeneca Gross Profit Driver Correlations

AstraZeneca Gross Profit Historical Pattern

AstraZeneca Gross Profit Peer Comparison

AstraZeneca PLC Current Valuation Drivers

AstraZeneca PLC ESG Sustainability

AstraZeneca Fundamentals

About AstraZeneca PLC Fundamental Analysis

Pair Trading with AstraZeneca PLC

Moving together with AstraZeneca Stock

Moving against AstraZeneca Stock

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY